PPH.US VanEck Pharmaceutical ETF
- Total assets
- 1.08B
- Expense ratio
- 0.36%
- Dividend yield
- 1.79%
- 1-year return
- +24.47%
- Holdings
- 25
- Since
- 2011
Fund data as reported by the issuer, updated Nov 17, 2026. Total assets are in the fund's base currency.
What does PPH.US invest in?
- Mostly US stocks (71.6%)
- Largest sector: Healthcare (96.9%)
- Largest region: North America (71.6%)
- Top 3 holdings: 40.6% of the fund
Asset allocation
- US stocks 71.6%
- Non-US stocks 29.9%
- Cash 0.0%
Top holdings
- Eli Lilly and Company 22.48%
- Merck & Company Inc 12.54%
- Novo Nordisk A/S 5.56%
- Teva Pharmaceutical Industries Ltd 5.02%
- McKesson Corporation 4.78%
VanEck Pharmaceutical ETF performance
Sharpe ratio 1.00- This year
- +19.41%
- 1 year
- +24.47%
- 3 years
- +19.94%
- 5 years
- +11.75%
Volatility 17.0% over 1 year and 14.2% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
PPH.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Full fund profileVanEck Pharmaceutical ETF top holdings
71.6% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Eli Lilly and Company LLY.US | Healthcare | United States | 22.48% |
| Merck & Company Inc MRK.US | Healthcare | United States | 12.54% |
| Novo Nordisk A/S NVO.US | Healthcare | United States | 5.56% |
| Teva Pharmaceutical Industries Ltd TEVA.TA | Healthcare | Israel | 5.02% |
| McKesson Corporation MCK.US | Healthcare | United States | 4.78% |
| Pfizer Inc PFE.US | Healthcare | United States | 4.59% |
| Bristol-Myers Squibb Company BMY.US | Healthcare | United States | 4.50% |
| Cencora Inc. COR.US | Healthcare | United States | 4.44% |
| GSK plc GSK.US | Healthcare | United States | 4.11% |
| AbbVie Inc ABBV.US | Healthcare | United States | 3.62% |
The 10 largest of 25 holdings.
PPH.US sector exposure
- Healthcare96.9%
Share of the stocks in the fund.
PPH.US regional exposure
- North America71.6%
- Europe Developed13.2%
- United Kingdom11.5%
- Africa/Middle East4.8%
- Japan2.9%
Share of the stocks in the fund.
Company size
Average market cap 215B- Mega cap46.2%
- Big cap41.4%
- Medium cap8.4%
- Small cap3.3%
- Micro cap0.4%
VanEck Pharmaceutical ETF fund profile
- Fund name
- VanEck Pharmaceutical ETF
- Ticker
- PPH.US
- Exchange
- USA Stocks
- Issuer
- VanEck
- Fund website
- vaneck.com/funds/PPH.aspx
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Dec 20, 2011
- Trading currency
- USD
- Expense ratio
- 0.36%
- Annual turnover
- 0.2%
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.